
The flow-based route required minimal manual intervention and was achieved despite poor solubility of many reaction components

UK chemists have used a combination of flow chemistry methods with solid-supported scavengers and reagents to synthesise the active pharmaceutical ingredient, imatinib, of the anticancer drug Gleevec. The method avoids the need for any manual handling of intermediates and allows the drug to be synthesised in high purity in less than a day.
Gleevec, developed by Novartis, is a tyrosine kinase inhibitor used for the treatment of chronic myeloid leukaemia and gastrointestinal stromal tumours.

READ ALL AT
http://www.rsc.org/chemistryworld/2013/01/flow-synthesis-anticancer-drug
| IMATINIB |
|---|
CREDIT
http://www.veomed.com/va041542042010

‘Wrapping’ Gleevec Fights Drug-Resistant Cancer, Study Shows
http://www.sciencedaily.com/releases/2007/05/070501115127.htm
The anti-cancer drug Gleevec® is far more effective against a drug-resistant strain of cancer when the drug wraps the target with a molecular bandage that seals out water from a critical area. This image shows the bandage (black box) on the modified version of the drug, WBZ-7. (Credit: Image courtesy of Rice University)
A new study in Cancer Research finds that the anti-cancer drug Gleevec® is far more effective against a drug-resistant strain of cancer when the drug wraps the target with a molecular bandage that seals out water from a critical area.
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....


Reblogged this on Fathisaffar.
LikeLike
Reblogged this on MedCheminAustralia.
LikeLike
Reblogged this on MEDCHEMEGYPT.
LikeLike
Thank you for giving this useful information.Really helpful
plz visit us Anticancer drugs in Mumbai
LikeLike